The immunohistochemical staining of c-MYC was implemented by FITC-conjugated IgG and c-MYC antibody (green). Control group (a) and CSO-treated group (b) showed high c-MYC concentration. Liposomal-doxorubicin-treated group (c) indicated low c-MYC concentration compared to control. The analysis of CSO/liposomal-doxorubicin group (d) showed increased c-MYC content than DOX-treated group. The sections were analyzed under fluorescence microscope (Magnification x100).